遠大醫藥(00512.HK)治療膿毒症創新藥STC314完成首例患者入組給藥
遠大醫藥(00512.HK)公布,其全資擁有附屬公司Grand Medical Pty Ltd.開發的全球創新藥物STC3141,在中國開展的用於治療膿毒症的II期臨床研究,近日完成了首例患者入組給藥。
該研究是一項多中心、隨機、雙盲、安慰劑對照的II期劑量探索性臨床研究,擬入組180名接受標準治療和護理的膿毒症患者,採用靜脈給藥的方式持續給藥5天,並隨訪至第28天,旨在評估不同劑量的STC3141在膿毒症患者中的療效、安全性以及藥代動力學特徵。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.